SecBot SecBot
SECBOTREPLAY Home › Report › HRMY

HRMY · Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY),…

Harmony Biosciences Holdings, Inc. · 8-K filed May 7, 2026 at 09:24 ET

At the news

MIXEDIMPACT 5/10

8-K filed May 7, 2026 at 09:24 ET

Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY), slightly below consensus of $220.8M. GAAP diluted EPS of $0.55 missed consensus of $0.93 by 41%, driven by $32M in upfront license payments. The company reaffirmed FY2026 revenue guidance of $1.0B-$1.04B, citing continued WAKIX growth and pipeline progress.

  • Q1 2026 net product revenue $215.4M, +17% YoY ($184.7M)
  • GAAP net income $32.5M ($0.55 diluted) vs $45.6M ($0.78) in Q1 2025
  • EPS missed consensus ($0.93) by 41% due to $32M in upfront license payments ($0.45 after-tax impact)
  • Reiterated FY2026 revenue guidance of $1.0B-$1.04B

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access